omtebrutideg   Click here for help

GtoPdb Ligand ID: 14625

Synonyms: ABBV-101 | Compound 1 [US20240109877]
Compound class: Synthetic organic
Comment: Omtebrutideg is the INN for a Bruton tyrosine kinase PROTAC degrader. It is proposed for antineoplastic effects. The structure indicates that it is designed to engage the cereblon (CRBN) E3 ubiquitin ligase. Available evidence suggests that omtebrutideg is likely the INN for Abbvie's lead BTK PROTAC ABBV-101 [2-3]. Targeted protein degradation is intended as a strategy to overcome BTK inhibitor resistance in B cell malignancies.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 13
Hydrogen bond donors 3
Rotatable bonds 13
Topological polar surface area 168.05
Molecular weight 771.91
XLogP 1.27
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC(=CC=C1[C@@H](C)NC(=O)C2=NC(=NO2)C(C)(C)C)C3=NC=NC(=C3)NC4=CC=C(C=N4)N5CCN(CCC6=CC=C(C=C6)N7CCC(=O)NC7=O)C[C@@H]5C
Isomeric SMILES C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=NC=NC(=C3)C4=CC(=C(C=C4)[C@@H](C)NC(=O)C5=NC(=NO5)C(C)(C)C)C)CCC6=CC=C(C=C6)N7CCC(=O)NC7=O
InChI InChI=1S/C42H49N11O4/c1-26-21-30(9-13-33(26)28(3)46-38(55)39-49-40(50-57-39)42(4,5)6)34-22-36(45-25-44-34)47-35-14-12-32(23-43-35)52-20-19-51(24-27(52)2)17-15-29-7-10-31(11-8-29)53-18-16-37(54)48-41(53)56/h7-14,21-23,25,27-28H,15-20,24H2,1-6H3,(H,46,55)(H,48,54,56)(H,43,44,45,47)/t27-,28+/m0/s1
InChI Key IFISVDOJTJUTBK-WUFINQPMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
ABBV-101 was progressed as a clinical candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05753501 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Phase 1 Interventional AbbVie